CN109498799A

CN109498799A - It is a kind of for treating the medical composition and its use of myelosis, osteocarcinoma

Info

Publication number: CN109498799A
Application number: CN201910002938.XA
Authority: CN
Inventors: 曹帅
Original assignee: Individual
Current assignee: Individual
Priority date: 2016-03-13
Filing date: 2016-03-13
Publication date: 2019-03-22
Also published as: CN109432398A; CN109395058A; CN105688185B; CN105688185A

Abstract

The invention discloses application of the pharmaceutical composition in the drug of preparation treatment osteocarcinoma and myeloproliferative disorder, described pharmaceutical composition contains GATA polypeptide, can also be administered in combination with bortezomib.Its effective therapeutic dose is 0.1~20mg/Kg weight, can be oral administration, intravenous injection administration, subcutaneous administrations, administered intramuscular when administration.Experiments have shown that: polypeptide of the invention can inhibit growth of tumour cell, have good inhibiting effect to osteocarcinoma and myeloproliferative disorder, tool has been widely used.

Description

It is a kind of for treating the medical composition and its use of myelosis, osteocarcinoma

Technical field

The present invention relates to preparation treatment myelosis, the drug of osteocarcinoma and its applications.

Background technique

The cause of disease of bone tumour is unknown so far, thinks that damage is especially chronic slight damage, chronic infection can cause in the past Bone tumour.Bone tumour age of onset male is 15~24 years old, and women is 5~14 years old, may with the growth of different sexes bone with it is interior The morning and evening for secreting development is related with length of time.Huppert's disease is the malignant tumour of thick liquid cell paraplasm, a kind of progress The tumor disease of property.It is characterized in that bone marrow plasma cells tumor and monoclonal immunoglobulin (IgG, IgA, IgD or IgE) or Bence Jones protein (free monoclonicity κ or Y light chain) hyperplasia, Huppert's disease is often accompanied by multiple molten Bone damage, hypercalcinemia, anaemia, kidney damage, and the neurological susceptibility of bacterial infection is increased, normal immunoglobulin Generate suppressed, disease incidence is estimated as 2-3/10 ten thousand, male to female ratio 1.6:1, most patient age > 40 year old.It there is no radical cure at present Therapy, still based on chemotherapy, high-dose chemotherapy is after solution, it is contemplated that itself or allogeneic bone marrow deposit transplanting.

The differentiation of myelodysplastic syndrome (myelodysplastic syndrome, MDS) hemopoietic stem cell proliferation is different Hematopoietic disorder caused by often.It is mainly shown as peripheral blood whole blood trace elements, bone marrow cell proliferation, mature and juvenile cell There is paramophia i.e. morbid hematopoiesis.Clinical manifestation is that hematopoietic cell different degrees of anomalous variation occurs on quality and quantity.It has Body clinical manifestation be anaemia, can with infection or bleeding, some patients can be asymptomatic.Some patientss can have a liver, spleen, and lymph node is light Enlargement is spent, small number of patients can have breastbone tenderness, rib cage or membra arthralgia.Blood picture can be in whole blood trace elements or any system And two be haemocyte reduce.Nineteen eighty-two establishes name of disease by FAB cooperative groups suggestion, and is five types: refractory anemia by MDS points；It is difficult The property controlled anaemia increases with cyclic annular sideroblast；Refractory anemia with excess of blasts, the refractory anemia in transformation is with former Beginning cytosis；Chronic grain _ monocytic leukemia.

Short alkali thatch is perennial acrophyta, has cold-resistant, drought-enduring plant, and inventor passes through biological library batch and sieves Choosing finds that short alkali thatch has stronger oxidation resistant ability, wherein there may be the substances for inhibiting cancer.

The drug for the treatment of myeloproliferative disorder is concentrated mainly on Chinese medicine composition and T-2 toxin at present, but these sides Method all inevitably generates certain side effect to human body, and therapeutic effect is not unusual ideal.Therefore, one is developed Efficient, the harmless drug of kind seems extremely urgent.

Summary of the invention

For the above-mentioned prior art, the present invention provides a kind of new pharmaceutical compositions for treating osteocarcinoma and myelosis It is abnormal.

A technical solution of the invention be it is a kind of for treating the pharmaceutical composition of myeloma, by GATA polypeptide and Pharmaceutically acceptable carrier is constituted.Shown in the sequence of the polypeptide such as GATA-1~29 are any, sequence is corresponded respectively to Shown in SEQ ID NO:1-29.

The present invention additionally provides a kind of preparation methods of polypeptide, this method comprises: weighing short alkali thatch blade 2g, match after smashing to pieces The PBS aqueous solution that concentration of substrate is 5% is made, adjusts pH to 8.0, trypsase 4000U/g blade, hydrolysis temperature 50 is added DEG C, after digesting 90min, enzymolysis liquid is brought rapidly up to 90 DEG C, keeps 20min, carries out destroy the enzyme treatment.Then it is rapidly cooled to room Temperature is being centrifuged 15min with 3000r/min, is taking supernatant.According to 100 grams: 100ml ratio in wet macroporous absorbent resin Tryptose enzymolysis liquid is added in DA201-C, 25 DEG C keep 180min, revolving speed 150r/min in constant-temperature table, with 75% second Alcoholic solution elutes 120min, collects eluent in different time periods.The band for recycling small-molecular-weight, is obtained the sequence of 78 small peptides Column.By verifying, wherein thering are 29 small peptides to have the function of that cancer cell is inhibited to be proliferated and killing cancer cell.According to chromatographic column The middle different peak separation time, corresponding small peptide can be obtained in batches.Conventional, the polypeptide passes through artificial synthesized side Method can batch be used for industrialized application, avoid insufficient raw material, bring limitation.

In other embodiments, synergistic effect allows one or more other therapeutic agents and polypeptide of the invention to criticize Quasi- dosage combinations are given, but have and be higher than expected efficiency.

In a typical implementation, polypeptide is enough to allow with 0.5mg/kg to 20mg/kg intravenous administration with concentration Pharmaceutical composition exists.Include suitable for the peptide concentration in the composition and method in certain embodiments, still It is not limited thereto, at least about 0.5mg/kg, at least about 0.75mg/kg, at least about lmg/kg, at least about 2mg/kg, at least about 2.5mg/kg, at least about 3mg/kg, at least about 4mg/kg, at least about 5mg/kg, at least about 6mg/kg, at least about 7mg/kg, until Few about 8mg/kg, at least about 9mg/kg, at least about 10mg/kg, at least about llmg/kg, at least about 12mg/kg, at least about 13mg/ Kg, at least about 14mg/kg, at least about 15mg/kg, at least about 16mg/kg, at least about 17mg/kg, at least about 18mg/kg, at least About 19mg/kg, and at least about 20mg/kg.

Polypeptide can be given with single dose or multi-dose scheme.In general, polypeptide is in the period from about I hours to about 24 hours It inside gives, but was typically given within about I to 2 hours period.When dosage can repeat about I weeks to about 6 weeks or longer Between, 6 doses or more in total.Typically, dosage weekly, is repeated once every other week, or monthly, and minimum 6 Agent is to most 50 doses.

It can be oral administration, intravenous injection administration, subcutaneous administrations, administered intramuscular when administration.Benefit of the invention Myelodysplastic syndrome is treated with specific killing action of the polypeptide to cancer cell, acts on marrow and other hematopoiesis groups It knits, inhibits growth of tumour cell.There is good killing to osteocarcinoma and myeloproliferative disorder.

Specific embodiment

The present invention is further explained in the light of specific embodiments, these embodiments are merely to illustrate the present invention, and Do not limit the scope of the invention.

The acquisition of 1 polypeptide of embodiment

Short alkali thatch blade 2g is weighed, the PBS aqueous solution that concentration of substrate is 5% is configured to after smashing to pieces, pH to 8.0 is adjusted, is added Trypsase 4000U/g blade, hydrolysis temperature are 50 DEG C, and after digesting 90min, enzymolysis liquid is brought rapidly up to 90 DEG C, is kept 20min carries out destroy the enzyme treatment.Then it is rapidly cooled to room temperature, 15min is being centrifuged with 3000r/min, is taking supernatant.According to 100 Gram: tryptose enzymolysis liquid is added in the ratio of 100ml in wet macroporous absorbent resin DA201-C, and 25 DEG C keep in constant-temperature table 180min, revolving speed 150r/min elute 120min with 75% ethanol solution, collect eluent in different time periods.Recycling The sequence of 78 small peptides is obtained in the band of small-molecular-weight.By verifying, cancer cell is inhibited to increase wherein there are 29 small peptides to have Grow and kill the function of cancer cell.The sequence of the polypeptide is as any shown such as GATA-1~29 respectively, and sequence respectively corresponds Shown in SEQ ID NO:1-29.

The preparation of 2 pharmaceutical composition of embodiment

0.01 part of GATA-1 polypeptide, 1 part of starch, honey element or/and sucrose is taken to be used as 0.1 part of sweetener, benzoic acid in right amount, It mixes, crosses 50 meshes, after sterilizing, packaging.

The polypeptide of GATA-2~29 is also all prepared into corresponding composition according to the preparation method of GATA-1 polypeptide respectively.

The mixing of embodiment 3 pharmaceutical composition and other preparations

GATA-1 polypeptide and bortezomib are mixed according to the ratio of 1:0.75, then using mixed drug weight as Basic number adds 1 part of starch, honey element or/and sucrose and is used as 0.1 part of sweetener, benzoic acid in right amount, mixes, and crosses 50 mesh Sieve, after sterilizing, packaging.

The detection of 4 drug safety of embodiment

According to the verification method of this field routine, it can be deduced that the present invention confirms safe and non-toxic, experiment knot through animal experiment Fruit is as follows with conclusion:

(1) acute toxicity testing shows: according to acute toxicity dose grading standard, belonging to practical nontoxicity grade；

(2) Micronucleus test, sperm malformation test, Salmonella reversion test result are feminine gender；

(3) 30 days feeding trials: experimental animal growing state is good, hematological examination, biochemical analysis, main dirty body ratio And histological indications are compared with the control group, are showed no exception, it was demonstrated that the present invention is safe and non-toxic.

The experiment of 5 pharmaceutical activity of embodiment

(1) cell culture

Rat Osteosarcoma Cell system UMR-106, which is cultivated in the FCS-1640 complete culture solution of 100mL/L, (contains HEPES 25mol/L), the next day, changes liquid, passes in time.Cell growth condition is detected using mtt assay, until cell grows into 3.0*10⁸I.e. It can.

(2) preparation of Rat Model of Osteosarcoma

The UMR-106 for collecting culture, is washed 1 time, adjusts cell concentration；Subcutaneously SD rat is inoculated on the outside of right hind 100ml cell suspension 0.5mL 15 days after inoculation, takes 20 qualified SCID mices to be randomly divided into two groups, control group intratumor injection 2ml physiological saline, experimental group will be dissolved in the conjunction object of the drug of ethyl alcohol mixed liquor of normal saline according to the agent of 1.0mg/kg weight Measure intratumor injection.It the 1st after administration, measures within 2,3,4,5 weeks tumour major diameter a and minor axis b weekly with vernier caliper, and calculates average straight Diameter, i.e. r=(a+b)/2.After about 5 weeks, tumour can grow into suitable volume.Take the qualified SCID for having injected cell small Mouse, control group intratumor injection 2ml physiological saline, experimental group will be dissolved in the pharmaceutical composition of ethyl alcohol mixed liquor of normal saline according to The dosage of 2.0mg/kg weight is injected intraperitoneally.0th, 10,20 day measurement subcutaneous transplantation tumor longest diameter (a) and vertical diameter after administration (d), tumour relative volume is calculated, the results are shown in Table 1 drug to the inhibiting effect (mm of Huppert's disease volume³)

As it can be seen from table 1 drug of the invention has the function of preferably inhibiting tumour growth, and can be significant Reduce the volume of tumour.The function of the growth for the inhibition tumour that it can be cooperateed with especially is administered in combination with bortezomib.GATA- 2~29 polypeptide and bortezomib administering drug combinations, which can achieve, is administered in combination identical technology effect with GATA-1 and bortezomib Fruit, specific value will not repeat them here.

Sequence table

<110>Cao Shuai

<120>a kind of for treating the medical composition and its use of myelosis, osteocarcinoma

<160> 29

<170> SIPOSequenceListing 1.0

<210> 1

<211> 18

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 1

Ala Gln Tyr Gln Trp Gly Lys Asp His Arg Asn Phe Pro Thr Gly Asn

1 5 10 15

Glu Tyr

<210> 2

<211> 18

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 2

Trp Phe Leu Pro Trp Gly Val Gln Leu His Cys Cys His Pro His Phe

1 5 10 15

Leu His

<210> 3

<211> 18

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 3

Trp Gly Gly Gly Trp Trp Ser Ser Arg Gly Asp His Ser Gly Val Arg

1 5 10 15

Lys Ala

<210> 4

<211> 18

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 4

Val Gln His Ala Trp Lys Glu Thr Arg Ile Arg Trp Trp Gln Gly Arg

1 5 10 15

Lys Asn

<210> 5

<211> 18

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 5

Ser Arg Ser Gln Pro Tyr Arg Phe Gly Met Met Ser Ser Cys Glu Arg

1 5 10 15

Val Asp

<210> 6

<211> 18

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 6

Ala Asn Ile Asp Thr Gln Lys Pro Ala Arg Ile Asp His Thr Ser Asn

1 5 10 15

Met Leu

<210> 7

<211> 18

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 7

His Met Tyr Asn His Pro Leu Thr Met Ala Trp Met Ile Pro Thr Phe

1 5 10 15

His Arg

<210> 8

<211> 18

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 8

Ala Ser Trp Thr Ala Tyr Gln Trp Asp Phe His Ser His Asp Tyr Lys

1 5 10 15

Phe Ile

<210> 9

<211> 18

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 9

Ile His Asn His Glu Arg Val Ala Thr Pro His His Cys Arg Gln Gln

1 5 10 15

Arg Trp

<210> 10

<211> 18

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 10

Arg Tyr His Gly Arg Arg Tyr Tyr Lys Arg Ala Pro Leu Pro His Thr

1 5 10 15

Pro Trp

<210> 11

<211> 17

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 11

Arg Val Thr Gln Leu Gly Cys Gln Val Ser Gln Pro Ser Trp Pro Asn

1 5 10 15

Pro

<210> 12

<211> 16

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 12

Val Leu Leu Arg Glu Trp Ser Thr Ser Arg Arg Asn Trp Cys Gly Lys

1 5 10 15

<210> 13

<211> 17

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 13

Val Trp Arg Leu Arg Ser Asp Pro Asn Asp His Cys Met Thr Cys Asn

1 5 10 15

Tyr

<210> 14

<211> 16

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 14

Trp Gln Ile Pro Phe Ser Met Trp Tyr Val Trp Trp Arg Cys Asp Ala

1 5 10 15

<210> 15

<211> 17

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 15

Ile Ser Arg His Ser Val Phe Lys Val Gln Lys Tyr Gln Phe Leu Glu

1 5 10 15

Pro

<210> 16

<211> 16

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 16

Leu Gln Ala Val Lys Gln Ser Ile Pro Ser Thr Asn Arg Lys Val Arg

1 5 10 15

<210> 17

<211> 17

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 17

Gly Pro Ile Gly Phe Gly Tyr Cys Gln Gln Gln Ser Tyr Arg Val Gly

1 5 10 15

Asn

<210> 18

<211> 16

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 18

Gln Asp His Gln Gln Trp Glu Gln Trp Ser His Ser Ser Lys Pro Asp

1 5 10 15

<210> 19

<211> 17

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 19

Gln Glu His Glu His Ser Trp Arg Gly Thr Arg Lys Gly Asp Lys Asp

1 5 10 15

Ser

<210> 20

<211> 16

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 20

Lys His Gln Leu Arg Pro Arg Ser Ala Val Gly Gln Trp Gly Phe Ala

1 5 10 15

<210> 21

<211> 17

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 21

Tyr Gly Ser Ala Trp Lys Met Lys Asp Lys Thr Arg Met Arg Asn Asp

1 5 10 15

Gly

<210> 22

<211> 16

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 22

His Ser Arg His Ile Trp Ala Met Ser Phe Ala Ala Glu Tyr Thr Gly

1 5 10 15

<210> 23

<211> 17

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 23

Thr Phe Ile Leu Gly Gln Phe Ile Gly Gln Gly Gln Glu Cys Gly Val

1 5 10 15

Lys

<210> 24

<211> 16

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 24

Arg Tyr Leu Ser Ser Arg Arg Glu Cys Gly Arg Arg Gln Phe Pro Cys

1 5 10 15

<210> 25

<211> 17

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 25

Gly Phe Met Thr Arg Thr Thr Thr His Gln Arg Tyr Cys Ser Gln Trp

1 5 10 15

Phe

<210> 26

<211> 16

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 26

Pro Gln Ser Ala His Trp Leu Gln Val Asn Asn Cys Leu Ser Ala Phe

1 5 10 15

<210> 27

<211> 17

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 27

Val Val Val Cys Ala Val Leu Asp Gln Val Thr Glu Thr Cys Asp Lys

1 5 10 15

Val

<210> 28

<211> 16

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 28

Ile Asn Arg Thr Leu Ala Cys Gln Leu Gly Leu Leu Gln Trp Gly Trp

1 5 10 15

<210> 29

<211> 17

<212> PRT

<213>artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)

<400> 29

Trp Asn Gly Trp Ala Arg Arg Gly Ser Ala Ser Trp Gly Met Ser Ile

1 5 10 15

Asn

Claims

1. a kind of for treating the pharmaceutical composition of myelosis, osteocarcinoma, characterized in that take 0.01 part of polypeptide, 1 part of starch, sweet tea Sweet element or/and sucrose are used as 0.1 part of sweetener, benzoic acid in right amount, mix, and cross 50 meshes, after sterilizing, packaging.

2. pharmaceutical composition as described in claim 1, it is characterised in that: the polypeptide is GATA-2 polypeptide, sequence SEQ Shown in ID NO:2.

3. composition according to claim 1 to 2, characterized in that bortezomib can also be added.

4. pharmaceutical composition described in claim 1-3 is used for answering for the drug of specific treatment myelosis, osteocarcinoma in preparation With.

5. a kind of polypeptide, characterized in that for sequence shown in SEQ ID NO:2.